Characteristics of patients with SCD developing therapy-related myeloid malignancy after allogeneic hematopoietic cell transplantation at the National Institutes of Health Clinical Center
| Patient ID . | SCD complications . | Age at AlloHCT, y . | Donor type . | Time from transplant to graft rejection . | Time from transplant to myeloid malignancy, y . | Cytogenetics at myeloid malignancy diagnosis . | TP53 mutation and VAF at myeloid malignancy diagnosis . |
|---|---|---|---|---|---|---|---|
| 1 | Stroke, CRI, recurrent VOC | 37 | Haplo | 73 d | 2 | Complex | c.524G>A, 72.4% in bone marrow |
| 2 | Recurrent VOC, chronic pain | 37 | HLA-matched | 6 mo | 2.5 | Complex* | c.658T>C, 4.5% in bone marrow |
| 3 | ESRD, pHTN, diastolic dysfunction | 44 | Haplo | 7 mo | 5 | 7q deletion | N/A |
| Patient ID . | SCD complications . | Age at AlloHCT, y . | Donor type . | Time from transplant to graft rejection . | Time from transplant to myeloid malignancy, y . | Cytogenetics at myeloid malignancy diagnosis . | TP53 mutation and VAF at myeloid malignancy diagnosis . |
|---|---|---|---|---|---|---|---|
| 1 | Stroke, CRI, recurrent VOC | 37 | Haplo | 73 d | 2 | Complex | c.524G>A, 72.4% in bone marrow |
| 2 | Recurrent VOC, chronic pain | 37 | HLA-matched | 6 mo | 2.5 | Complex* | c.658T>C, 4.5% in bone marrow |
| 3 | ESRD, pHTN, diastolic dysfunction | 44 | Haplo | 7 mo | 5 | 7q deletion | N/A |
A total of 76 patients received AlloHCT for HbSS at this center; myeloid malignancy was only seen within those who did not engraft
CRI, chronic renal insufficiency; ESRD, end-stage renal disease; Haplo, haploidentical donor; N/A, not available; pHTN; pulmonary hypertension.
Patient 2 had complex cytogenetics at graft rejection 2 years before formal myeloid malignancy diagnosis (no aspirate collected at a later point).